FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
A new study confirms that biosimilar ranibizumab matches innovator Lucentis in treating myopic choroidal neovascular membrane ...
Biosimilars revolutionize health care access in Latin America, offering cost savings and improved treatment availability for ...
While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...
Study authors measured savings, conversions to biosimilars, and payer policies for 3 originator brands Using commercial and public payer data, investigators observed that payer utilization management ...
Sophia Z. Humphreys, PharmD, MHA, BCBBS, of Sutter Health in Sacramento, California, details the regulatory decisions from 2022, what's to come in 2023, and how the US biosimilars market is expected ...
Sarfaraz K. Niazi, PhD, takes a look at the European Medicines Agency's (EMA) announcement that it will investigate whether comparative efficacy tests should be needed for a biosimilar to receive ...
Bevacizumab-bvzr…pegfilgrastim-bmez…infliximab-axxq…. Have you ever wondered what is behind the seemingly random letter strings attached to the nonproprietary names (also known as “proper names”) of ...
The FDA approved Celltrion USA’s Zymfentra (infliximab-dyyb), the world’s first and only subcutaneous infliximab product. Zymfentra is approved as a novel drug, and its development is based on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback